false000180373700018037372023-08-092023-08-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 9, 2023
Enhabit, Inc.
(Exact name of registrant as specified in its charter)

Delaware001-4140647-2409192
(State or other jurisdiction (Commission(IRS Employer
of incorporation) File Number) Identification No.)

6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206
(Address of principal executive offices, including zip code)
(214) 239-6500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareEHABNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02. Results of Operations and Financial Condition.*
On August 9, 2023, Enhabit, Inc. (the “Company”) issued a press release reporting the financial results of the Company for the quarter ended June 30, 2023. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.*
A copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Thursday, August 10, 2023 is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
Exhibit Number
Description
104Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

* The information in Item 2.02 and 7.01, including Exhibit 99.1 and Exhibit 99.2, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
ENHABIT, INC.
By:/s/ Dylan C. Black
Name:Dylan C. Black
Title:General Counsel
Dated: August 9, 2023

Exhibit 99.1

enhabit_hhhxlogoxverticalx.jpg


Enhabit Reports Second Quarter 2023 Financial Results
Revises Full-Year Guidance
Announces Intent to Launch Strategic Alternatives Process Subject to Satisfaction of Conditions in Tax Matters Agreement
Company to host a conference call tomorrow, August 10, 2023 at 10 AM EDT
DALLAS, TX – August 9, 2023 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2023.
“During the second quarter, we negotiated ten new contracts with Medicare Advantage payors, increased our clinical staff with 203 net new full-time nursing hires, and continued to outperform the industry average with a 30-day hospital readmission rate that is 370 basis points better than the national average,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “While we continue to make progress with our strategic initiatives, the pace of the progress has not been fast enough in 2023 to meet our initial guidance. We remain confident our teams’ relentless efforts to retain staff, manage costs, and deliver high-quality care will enhance our value long term.”
QUARTERLY PERFORMANCE - CONSOLIDATED
•Net service revenue of $262.3 million
•Net loss of $74.1 million
•Adjusted EBITDA of $23.9 million
•Loss per diluted share of $1.49
•Adjusted earnings per share of $0.04
RECENT COMPANY HIGHLIGHTS
•Negotiated ten new Medicare Advantage payor contracts in the second quarter
•Shifted approximately 5% of previous non-episodic visits into non-episodic payor innovation contracts at improved per visit rates
•Continued strong growth in home health Medicare Advantage admissions with non-episodic admissions up 38.0% driving total admission growth of 3.2% year over year
•Continued recruiting success adding 203 net new full-time nursing hires in the second quarter
•Opened two de novo home health locations in Montana in April and one hospice de novo location in Texas in May
1

•Hospice cost per day stabilized sequentially
•30-day hospitalization readmission rate is 370 basis points better than the national average
FINANCIAL RESULTS
Consolidated
($ in millions, except per share data)Q2 '23 vs. '22
20232022
Home health net service revenue$213.8$220.2(2.9)%
Hospice net service revenue48.547.81.5%
Total net service revenue$262.3$268.0(2.1)%
% of Revenue% of Revenue
Cost of services51.7%$(135.5)48.6%$(130.3)4.0%
Gross margin48.3%126.851.4%137.7(7.9)%
General & administrative expenses39.2%(102.7)36.1%(96.7)6.2%
Operating expenses90.8%(238.2)84.7%(227.0)4.9%
Other income (0.1)—
Equity earnings / noncontrolling interest0.30.7
Adjusted EBITDA$23.9$40.3(40.7)%
Adjusted EBITDA margin9.1%15.0%
Reported Diluted EPS$(1.49)$0.41(467.7)%
Adjusted EPS$0.04$0.47(91.5)%
The continued shift to more non-episodic admissions in home health and the resumption of sequestration reduced consolidated net service revenue and Adjusted EBITDA $10.5 million year over year.
Adjusted EBITDA decreased year over year primarily due to the continued shift to more non-episodic admissions in home health, incremental costs associated with being a stand-alone company, and the resumption of sequestration.
2

SEGMENT RESULTS
Home health
($ in millions)Q2 '23 vs. '22
20232022
Net service revenue$213.8$220.2(2.9)%
Cost of services111.4108.82.4%
Gross margin47.9%50.6%
General & administrative expenses$59.4$57.82.8%
Other income $(0.1)$—
Equity earnings / noncontrolling interest$0.3$0.6(50.0)%
Adjusted EBITDA$42.8$53.0(19.2)%
% Adj. EBITDA margin20.0%24.1%
Operational metrics (Actual Amounts)
Starts of care
Episodic admissions32,62836,106(9.6)%
Non-episodic admissions18,34713,29338.0%
Total admissions50,97549,3993.2%
Same-store total admissions growth1.7%
Episodic recertifications23,78825,993(8.5)%
Non-episodic recertifications9,5546,44748.2%
Total recertifications33,34232,4402.8%
Same-store total recertifications growth2.2%
Total starts of care84,31781,8393.0%
Completed episodes56,80862,691(9.4)%
Revenue per episode$2,913$2,972(2.0)%
Visits per episode14.615.0(2.7)%
Total visits1,205,8651,217,447(1.0)%
Non-episodic visits377,214275,67936.8%
Cost per visit$91$883.4%
The year-over-year decrease in revenue was due primarily to the continued payor mix shift to more non-episodic admissions and the resumption of sequestration. Revenue per episode decreased year over year primarily due to the resumption of sequestration and patient mix.
Adjusted EBITDA decreased year over year primarily due to the continued payor mix shift to more non-episodic admissions, the resumption of sequestration, and increased general and administrative expenses associated with new stores. Cost per visit increased year-over-year primarily due to increased contract labor, merit and market rate increases for clinical staff, and increased costs associated with employee group medical claims partially offset by improved clinical productivity.
3

Hospice
($ in millions)Q2 '23 vs. '22
20232022
Net service revenue$48.5$47.81.5%
Cost of services24.121.512.1%
Gross margin50.3%55.0%
General & administrative expenses$16.1$15.53.9%
Equity earnings / noncontrolling interest$—$0.1
Adjusted EBITDA$8.3$10.7(22.4)%
% Adj. EBITDA margin17.1%22.4%
Operational metrics (Actual Amounts)
Total admissions2,8372,8350.1%
Same-store total admissions growth(4.1)%
Patient days311,465313,718(0.7)%
Discharged average length of stay108109(0.9)%
Average daily census3,4233,447(0.7)%
Revenue per day$156$1522.6%
Cost per day$77$6911.6%
Net service revenue increased year over year primarily due to increased Medicare reimbursement rates.
Adjusted EBITDA decreased year over year primarily due to higher cost of services resulting from increased labor costs. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses.
TAX MATTERS AGREEMENT
Enhabit also announced today that it is undertaking steps to attempt to satisfy the conditions in its Tax Matters Agreement (“TMA”), dated June 30, 2022, with Encompass Health Corporation relating to certain transactions involving the Company. The conditions in the TMA include securing a tax opinion of legal counsel, satisfactory to Encompass Health in its sole and absolute discretion, that the actions taken by Enhabit would not jeopardize the tax-free treatment of the spin-off of Enhabit.
Upon satisfaction of these conditions, the Enhabit board, with the assistance of independent advisors, intends to launch a strategic alternatives process. As part of any such process, the board expects it would consider a wide range of options for the company including, among other things, a potential sale, merger or other strategic transaction. There can be no assurance that the conditions in the TMA will be satisfied, that Enhabit will initiate such a process, or if launched, that a process would result in Enhabit pursuing a particular transaction or other strategic outcome.
GUIDANCE
The Company revised its full-year 2023 guidance as follows:
4

($ in millions, except per share data)
Full-Year 20232023 Original Guidance 2023 Revised Guidance
Net Service Revenue$1,110 to $1,140$1,057 to $1,065
Adjusted EBITDA$125 to $140$100 to $107
Adjusted EPS$0.50 to $0.89$0.28 to $0.46
For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.
CONFERENCE CALL INFORMATION
The Company will host an investor conference call at 10 AM Eastern Time on August 10, 2023 to discuss its results for the second quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/923162031. Following the call, a replay will be available at Enhabit’s investor website.
ABOUT ENHABIT HOME HEALTH & HOSPICE
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 108 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
OTHER INFORMATION
Note regarding presentation of non-GAAP financial measures
The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, leverage ratios, adjusted EPS, and adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP.
The Company is unable to reconcile the guidance for Adjusted EBITDA and adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
Note regarding reconciliations of non-GAAP financial measures
This press release contains the reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial
1

measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.
Note regarding presentation of same-store comparisons
The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.
5
Enhabit, Inc. and Subsidiaries
Condensed Consolidated Statements of Income
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
($ in millions, except per share data)
Net service revenue$262.3 $268.0 $527.4 $542.3 
Cost of service, excluding depreciation and amortization135.5 130.3 268.1 260.0 
General and administrative expenses107.8 102.2 218.3 202.9 
Depreciation and amortization7.7 8.2 15.5 16.7 
Impairment of goodwill85.8 — 85.8 — 
Operating income(74.5)27.3 (60.3)62.7 
Interest expense and amortization of debt discounts and fees10.3 0.1 19.8 0.1 
Other income(0.1)— (0.1)— 
(Loss) income before income taxes and noncontrolling interests(84.7)27.2 (80.0)62.6 
Income tax (benefit) expense(10.6)6.4 (9.1)15.1 
Net (loss) income(74.1)20.8 (70.9)47.5 
Less: Net income attributable to noncontrolling interests0.3 0.7 0.8 1.3 
Net (loss) income attributable to Enhabit, Inc.$(74.4)$20.1 $(71.7)$46.2 
Weighted average common shares outstanding:
Basic49.8 49.6 49.8 49.6 
Diluted49.8 49.6 49.8 49.6 
(Loss) earnings per common share:
Basic (loss) earnings per share attributable to Enhabit, Inc. common stockholders$(1.49)$0.41 $(1.44)$0.93 
Diluted (loss) earnings per share attributable to Enhabit, Inc. common stockholders$(1.49)$0.41 $(1.44)$0.93 
6
Enhabit, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
June 30,
2023		December 31,
2022
($ in millions)
Assets
Current assets:
Cash and cash equivalents$34.4 $22.9 
Restricted cash2.1 4.3 
Accounts receivable147.6 149.6 
Income tax receivable3.9 11.4 
Prepaid expenses and other current assets11.6 23.6 
Total current assets199.6 211.8 
Property and equipment, net18.5 20.4 
Operating lease right-of-use assets49.3 42.0 
Goodwill1,061.7 1,144.8 
Intangible assets, net91.2 102.6 
Other long-term assets5.9 5.2 
Total assets$1,426.2 $1,526.8 
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt$22.5 $23.1 
Current operating lease liabilities11.7 14.0 
Accounts payable5.4 3.8 
Accrued payroll32.8 35.5 
Refunds due patients and other third-party payors7.1 8.3 
Accrued medical insurance8.2 7.5 
Other current liabilities35.8 40.7 
Total current liabilities123.5 132.9 
Long-term debt, net of current portion539.3 560.0 
Long-term operating lease liabilities37.5 28.1 
Deferred income tax liabilities18.1 28.6 
Other long-term liabilities0.6 1.9 
719.0 751.5 
Commitments and contingencies
Redeemable noncontrolling interests5.1 5.2 
Stockholders’ equity:
Enhabit, Inc. stockholders’ equity:675.2 741.7 
Noncontrolling interests26.9 28.4 
Total stockholders’ equity702.1 770.1 
Total liabilities and stockholders’ equity$1,426.2 $1,526.8 
7
Enhabit, Inc. and Subsidiaries
Condensed Consolidated Cash Flows
(Unaudited)
Six Months Ended June 30,
20232022
($ in millions)
Cash flows from operating activities:
Net (loss) income$(70.9)$47.5 
Adjustments to reconcile net (loss) income to net cash provided by operating activities—
Depreciation and amortization15.5 16.7 
Amortization of debt related costs0.5 — 
Impairment of goodwill85.8 — 
Stock-based compensation4.1 2.5 
Deferred tax benefit(11.0)(1.4)
Other, net0.9 (0.6)
Changes in assets and liabilities, net of acquisitions—
Accounts receivable1.9 13.4 
Prepaid expenses and other assets19.2 (2.7)
Accounts payable1.5 (0.8)
Accrued payroll(2.6)6.2 
Other liabilities(5.7)(5.8)
Net cash provided by operating activities39.2 75.0 
Cash flows from investing activities:
Acquisition of businesses, net of cash acquired(2.8)— 
Purchases of property and equipment(1.7)(4.5)
Other, net0.5 1.0 
Net cash used in investing activities(4.0)(3.5)
Cash flows from financing activities:
Principal borrowings on term loan— 400.0 
Principal payments on term loan(10.0)— 
Principal payments on debt— (0.4)
Borrowings on revolving credit facility— 170.0 
Payments on revolving credit facility(10.0)— 
Principal payments under finance lease obligations(1.8)(2.6)
Debt issuance costs(1.1)(4.4)
Distributions paid to noncontrolling interests of consolidated affiliates(2.5)(0.7)
Contributions from Encompass— 59.8 
Distributions to Encompass— (654.9)
Contributions from noncontrolling interests of consolidated affiliates— 7.4 
Other(0.5)— 
Net cash used in financing activities(25.9)(25.8)
Increase in cash, cash equivalents, and restricted cash 9.3 45.7 
Cash, cash equivalents, and restricted cash at beginning of year27.2 8.0 
Cash, cash equivalents, and restricted cash at end of period$36.5 $53.7 
8
Enhabit, Inc. and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share
Three Months Ended June 30,Six Months Ended
June 30,
2023202220232022
Earnings per share, as reported$(1.49)$0.41 $(1.44)$0.93 
Adjustments, net of tax:
Impairment of goodwill1.50 — 1.50 — 
Unusual or nonrecurring items that are not typical of ongoing operations(1)
0.03 0.06 0.07 0.09 
Income tax adjustments(2)
— — 0.01 — 
Adjusted earnings per share(3)
$0.04 $0.47 $0.14 $1.02 
(1)    Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.
(2)    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(3)    Adjusted EPS may not sum due to rounding.
9
Enhabit, Inc. and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share
Q2 QTD
2023
Adjustments
As ReportedImpairment of GoodwillUnusual or nonrecurring items that are not typical of ongoing operations
Income Tax Adjustments(3)
As Adjusted
($ in millions, except per share data)
Adjusted EBITDA(1)
$23.9 $— $— $— $23.9 
Impairment of goodwill(85.8)85.8 — — — 
Interest expense and amortization of debt discounts and fees(10.3)— — (10.3)
Depreciation and amortization(7.7)— — — (7.7)
Unusual or nonrecurring items that are not typical of ongoing operations(2)
(2.6)— 2.6 — — 
Stock-based compensation(2.6)— — — (2.6)
Gain on disposal or impairment of assets0.1 — — — 0.1 
Net loss before income tax expense, including noncontrolling interests(85.0)85.8 2.6 — 3.4 
Income tax benefit (expense)10.6 (11.1)(1.0)0.1 (1.4)
Net (loss) income attributable to Enhabit$(74.4)$74.7 $1.6 $0.1 $2.0 
Diluted earnings per share(4)
$(1.49)$1.50 $0.03 $— $0.04 
Diluted shares 49.8 49.8 
(1)    Reconciliation to GAAP provided on page 14.
(2)    Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense.
(3)    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(4)    Adjusted EPS may not sum due to rounding.
10
Enhabit, Inc. and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

Q2 QTD
2022
Adjustments
As ReportedUnusual or nonrecurring items that are not typical of ongoing operationsAs Adjusted
($ in millions, except per share data)
Adjusted EBITDA(1)
$40.3 $— $40.3 
Depreciation and amortization(8.2)— (8.2)
Unusual or nonrecurring items that are not typical of ongoing operations(2)
(4.1)4.1 — 
Stock-based compensation(1.2)— (1.2)
Stock-based compensation included in overhead allocation(0.6)— (0.6)
Gain on disposal or impairment of assets0.4 — 0.4 
Interest expense and amortization of debt discounts and fees(0.1)— (0.1)
Income before income tax expense26.5 4.1 30.6 
Provision for income tax expense(6.4)(1.0)(7.4)
Net income attributable to Enhabit$20.1 $3.1 $23.2 
Diluted earnings per share(3)
$0.41 $0.06 $0.47 
Diluted shares used in calculation49.6 49.6 
(1)    Reconciliation to GAAP provided on page 14.
(2)    Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review.
(3)    Adjusted EPS may not sum due to rounding.
11
Enhabit, Inc. and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

YTD
2023
Adjustments
As ReportedImpairment of GoodwillUnusual or nonrecurring items that are not typical of ongoing operations
Income Tax Adjustments(3)
As Adjusted
($ in millions, except per share data)
Adjusted EBITDA(1)
$49.2 $— $— $— $49.2 
Impairment of goodwill(85.8)85.8 — — — 
Interest expense and amortization of debt discounts and fees(19.8)— — — (19.8)
Depreciation and amortization(15.5)— — — (15.5)
Unusual or nonrecurring items that are not typical of ongoing operations(2)
(4.9)— 4.9 — — 
Stock-based compensation(4.1)— — — (4.1)
Gain on disposal or impairment of assets0.1 — — — 0.1 
Net loss before income taxes, including noncontrolling interests(80.8)85.8 4.9 — 9.9 
Income tax benefit (expense) 9.1 (11.1)(1.6)0.5 (3.1)
Net (loss) income attributable to Enhabit$(71.7)$74.7 $3.3 $0.5 $6.8 
Diluted earnings per share(4)
$(1.44)$1.50 $0.07 $0.01 $0.14 
Diluted shares 49.8 49.8 
(1)    Reconciliation to GAAP provided on page 14.
(2)    Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense.
(3)    Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation.
(4)    Adjusted EPS may not sum due to rounding.
12
Enhabit, Inc. and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

YTD
2022
Adjustments
As ReportedUnusual or nonrecurring items that are not typical of ongoing operationsAs Adjusted
($ in millions, except per share data)
Adjusted EBITDA(1)
$87.3 $— $87.3 
Depreciation and amortization(16.7)— (16.7)
Unusual or nonrecurring items that are not typical of ongoing operations(2)
(6.1)6.1 — 
Stock-based compensation(2.5)— (2.5)
Stock-based compensation included in overhead allocation(1.1)— (1.1)
Gain on disposal or impairment of assets0.5 — 0.5 
Interest expense and amortization of debt discounts and fees(0.1)— (0.1)
Income before income tax expense61.3 6.1 67.4 
Provision for income tax expense(15.1)(1.5)(16.6)
Net income attributable to Enhabit$46.2 $4.6 $50.8 
Diluted earnings per share(3)
$0.93 $0.09 $1.02 
Diluted shares used in calculation49.6 49.6 
(1)    Reconciliation to GAAP provided on page 14.
(2)    Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review.
(3)    Adjusted EPS may not sum due to rounding.
13
Enhabit, Inc. and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA








Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
($ in millions)
Net (loss) income$(74.1)$20.8 $(70.9)$47.5 
Impairment of goodwill85.8 — 85.8 — 
Income tax (benefit) expense(10.6)6.4 (9.1)15.1 
Interest expense and amortization of debt discounts and fees10.3 0.1 19.8 0.1 
Depreciation and amortization7.7 8.2 15.5 16.7 
Unusual or nonrecurring items that are not typical of ongoing operations(1)
2.6 4.1 4.9 6.1 
Stock-based compensation2.6 1.2 4.1 2.5 
Net income attributable to noncontrolling interests(0.3)(0.7)(0.8)(1.3)
Gain on disposal or impairment of assets(0.1)(0.4)(0.1)(0.5)
Stock-based compensation included in overhead allocation— 0.6 — 1.1 
Adjusted EBITDA$23.9 $40.3 $49.2 $87.3 

(1)    Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
($ in millions)
Net cash provided by operating activities$9.6 $33.6 $39.2 $75.0 
Interest expense, excluding amortization of debt discounts and fees10.1 0.1 19.3 0.1 
Unusual or nonrecurring items that are not typical of ongoing operations(1)
2.6 4.1 4.9 6.1 
Change in assets and liabilities, excluding derivative instruments1.2 (5.0)(15.0)(10.3)
Current portion of income tax expense0.7 7.6 1.916.5 
Net income attributable to noncontrolling interests in continuing operations(0.3)(0.7)(0.8)(1.3)
Stock-based compensation included in overhead allocation— 0.6 — 1.1 
Other— — (0.3)0.1 
Adjusted EBITDA$23.9 $40.3 $49.2 $87.3 
(1)     Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.
14
Enhabit, Inc. and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
($ in millions)
Net cash provided by operating activities$9.6 $33.6 $39.2 $75.0 
Capital expenditures for maintenance (1.1)(0.3)(1.7)(2.6)
Other working capital adjustments(0.5)(0.4)(1.0)(0.9)
Distributions paid to noncontrolling interests of consolidated affiliates— (0.2)(2.5)(0.7)
Items non-indicative of ongoing operating performance:
Unusual or nonrecurring items that are not typical of ongoing operations(1)
2.6 4.1 4.9 6.1 
Stock-based compensation included in overhead allocation— 0.6 — 1.1 
Adjusted free cash flow $10.6 $37.4 $38.9 $78.0 
(1)     Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review.







15

FORWARD-LOOKING STATEMENTS
Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. In addition, with respect to the Tax Matters Agreement (TMA) and the potential launch of a strategic alternative process, these factors include, our ability to receive Encompass Health Corporation’s approval to pursue a strategic transaction as required under the TMA and our ability to successfully pursue and complete a strategic transaction, as discussed above. Our Form 10-K and subsequent quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.

Investor Relations Contact                    
Jordan Loyd
InvestorRelations@ehab.com
469-860-6061

Media Contact
Erin Volbeda
Media@ehab.com
972-338-5141
16
Second Quarter Earnings Call Supplemental Information August 9, 2023

 
Enhabit Home Health & Hospice 2 Disclaimer Forward looking statements Statements contained in this presentation which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. In addition, with respect to the Tax Matters Agreement (“TMA”) and the potential launch of a strategic alternative process, these factors include, our ability to receive Encompass Health Corporation’s approval to pursue a strategic transaction as required under the TMA and our ability to successfully pursue and complete a strategic transaction. Our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which will be filed with the SEC, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this presentation. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this presentation. Note regarding presentation of non-GAAP financial measures This presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented at the end of this presentation. Our Form 8-K, furnished as of the date of this presentation with the SEC, provides further explanation and disclosure regarding Enhabit’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Note regarding presentation of same-store comparisons The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

 
Contents Results at a Glance 4 Consolidated Results 5-7 De Novos and Acquisitions 8 Home Health Segment 9-10 - Quality 11 Hospice Segment 12-13 Consolidated Adjusted EBITDA 14 Debt, Liquidity and Adjusted Free Cash Flow 15-16 Guidance 17-20 Appendix, Including Company Overview & Reconciliations to GAAP 21-32

 
Enhabit Home Health & Hospice 4 Home health continued strong growth in Medicare Advantage admissions; new agreements added Non-episodic admissions grew 38.0%, driving total admissions growth of 3.2% year over year. Continued progress in payor innovation resulted in ten new Medicare Advantage agreements negotiated during Q2. Continued high-quality outcomes; 30-day hospital readmission rate 370 basis points better than national average $262.3M Revenue $23.9M Adjusted EBITDA 50,975 Home Health Admissions 2,837 Hospice Admissions 56,808 Home Health Completed Episodes 3,423 Hospice Average Daily Census Hospice growth in revenue Admissions increased 0.1% year over year. Cost per day stabilized sequentially. Continued high-quality care; 250 basis points better than the national average for patient visits in the last days of life(1) $2,913 Home Health Revenue per Completed Episode $156 Hospice Revenue per Day $91 Home Health Cost per Visit $77 Hospice Cost per Day Reconciliations to GAAP provided on pages 35 to 37 Results at a Glance The continued home health payor mix shift and resumption of sequestration impacted revenue and Adjusted EBITDA. The home health payor mix shift and resumption of sequestration reduced consolidated net service revenue and Adjusted EBITDA approximately $10.5 million. Shifted approximately 5% of previous non-episodic visits into non-episodic payor innovation contracts at improved per visit rates $(1.49) Reported Diluted EPS $0.04 Adjusted Diluted EPS (1) Medicare fee for service claims data for CY 2022, source Trella Health.

 
Enhabit Home Health & Hospice 5 Consolidated Results ($ in millions, except per share data) Q2 '23 vs. '222023 2022 Home health net service revenue $213.8 $220.2 (2.9) % Hospice net service revenue $48.5 $47.8 1.5 % Total net service revenue $262.3 $268.0 (2.1) % % of Revenue % of Revenue Cost of services 51.7 % $(135.5) 48.6 % $(130.3) 4.0 % Gross margin 48.3 % $126.8 51.4 % $137.7 (7.9) % General & administrative expenses 39.2 % $(102.7) 36.1 % $(96.7) 6.2 % Operating expenses 90.8 % $(238.2) 84.7 % $(227.0) 4.9 % Other income $(0.1) $— Equity earnings / noncontrolling interest $0.3 $0.7 Adjusted EBITDA $23.9 $40.3 (40.7) % Adjusted EBITDA margin 9.1 % 15.0 % Reported Diluted EPS $(1.49) $0.41 (467.7) % Adjusted EPS (see calculations on slides 31 and 32) $0.04 $0.47 (91.5) % General & administrative expenses in the above table exclude: Unusual or nonrecurring items that are not typical of ongoing operations(1) $2.6 $4.1 Stock-based compensation $2.6 $1.2 Gain on disposal or impairment of assets $(0.1) $(0.4) Stock-based compensation included in overhead allocation $— $0.6 Reconciliations to GAAP provided on pages 35 to 37 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 6 Consolidated Results (continued) • The continued shift to more non-episodic admissions in home health and the resumption of sequestration impacted consolidated revenue. – Approximately 31% of total home health visits were non-episodic visits in Q2 2023, up from approximately 23% in Q2 2022. This payor mix shift decreased revenue approximately $8 million, net of the impact from improved pricing of payor innovation contracts. – The resumption of sequestration decreased revenue approximately $2.5 million in Q2 2023 ($2 million home health; $0.5 million hospice). Consolidated Adjusted EBITDA decreased $16.4 million, or 40.7% year over year Consolidated revenue decreased $5.7 million, or 2.1% year over year Reconciliations to GAAP provided on pages 35 to 37 • Adjusted EBITDA decreased primarily due to the continued shift to more non-episodic admissions in home health ($8 million), incremental costs associated with being a stand-alone company ($3.4 million) and the resumption of sequestration ($2.5 million).

 
Enhabit Home Health & Hospice 7 Consolidated Results (continued) Continued growth in Medicare Advantage Continued success in Recruitment and Retention • Continued increase in full-time nursing candidate pool drove 203 net new full-time nursing hires in Q2 2023. – Home health - 180 – Hospice - 23 • Continued success with payor innovation team – Ten new regional agreements negotiated in Q2 2023 > Of the ten, seven were negotiated at episodic rates and three at per visit rates – 37 agreements negotiated since inception of payor innovation team – During Q2 2023, we shifted approximately 5% of our previous non-episodic visits into non-episodic payor innovation contracts at improved per visit rates. > To Q2 2023, we estimate the visits performed contributed $0.7 million to revenue and Adjusted EBITDA. > We estimate this shift represents an approximate $3 million increase to revenue and Adjusted EBITDA annually, which is ahead of our previous estimate of $2 million for every 5% shift of non-episodic visits.

 
Enhabit Home Health & Hospice 8 De Novos and Acquisitions Strategically reinvesting for growth • Added 3 new de novo locations in Q2 2023 – Opened two home health locations in Q2 2023 (year-to-date home health de novo openings = 2) > Kalispell, Montana and Missoula, Montana began accepting patients in April 2023. – Opened one hospice location in Q2 2023 (year-to-date hospice de novo openings = 3) > Beaumont, Texas began accepting patients in May 2023. Home Health Hospice Total December 31, 2020 241 82 323 De Novo Locations Opened 0 3 3 Acquired Locations 11 11 22 Merged/Closed Locations (1) 0 (1) December 31, 2021 251 96 347 De Novo Locations Opened 1 3 4 Acquired Locations 2 6 8 Merged/Closed Locations (2) 0 (2) December 31, 2022 252 105 357 De Novo Locations Opened 2 3 5 Acquired Locations 1 0 1 YTD 2023 255 108 363 241 251 252 255 82 96 105 108 Home Health Hospice 12/31/20 12/31/21 12/31/22 YTD 2023 0 100 200 300 400 Location Count

 
Enhabit Home Health & Hospice 9 Home Health Segment ($ in millions) Q2 '23 vs. '222023 2022 Net service revenue $213.8 $220.2 (2.9) % Cost of services $111.4 $108.8 2.4 % Gross margin 47.9 % 50.6 % General & administrative expenses $59.4 $57.8 2.8 % Other Income $(0.1) $— Equity earnings / noncontrolling interest $0.3 $0.6 (50.0) % Adjusted EBITDA $42.8 $53.0 (19.2) % % Adj. EBITDA margin 20.0 % 24.1 % Operational metrics (Actual Amounts) Starts of care Episodic admissions 32,628 36,106 (9.6) % Non-episodic admissions 18,347 13,293 38.0 % Total admissions 50,975 49,399 3.2 % Same-store total admissions growth 1.7 % Episodic recertifications 23,788 25,993 (8.5) % Non-episodic recertifications 9,554 6,447 48.2 % Total recertifications 33,342 32,440 2.8 % Same-store total recertifications growth 2.2 % Total starts of care 84,317 81,839 3.0 % Completed episodes 56,808 62,691 (9.4) % Revenue per episode $2,913 $2,972 (2.0) % Visits per episode 14.6 15.0 (2.7) % Total visits 1,205,865 1,217,447 (1.0) % Non-episodic visits 377,214 275,679 36.8 % Cost per visit $91 $88 3.4 % Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 10 Home Health Segment (continued) Revenue declined $6.4 million, or 2.9%, primarily due to the continued payor mix shift to more non-episodic admissions and the resumption of sequestration. • Total admissions growth was driven by 38.0% year-over-year growth in non-episodic admissions. • The continued shift to more non-episodic admissions reduced revenue approximately $8 million, net of the $0.7 million impact from improved pricing of payor innovation contracts. • The resumption of sequestration reduced revenue approximately $2 million. • Revenue per episode decreased 2.0% year over year primarily due to the resumption of sequestration and patient mix. Adjusted EBITDA decreased primarily due to the continued payor mix shift to more non-episodic admissions ($8 million), the resumption of sequestration ($2 million), and increased general and administrative expenses associated with new stores. • Cost per visit increased 3.4% year over year primarily due to increased contract labor, merit and market rate increases for clinical staff, and increased costs associated with employee group medical claims partially offset by improved clinical productivity. Home health total admissions increased 3.2% year over year

 
Enhabit Home Health & Hospice 11 Clinical Expertise and High-Quality Outcomes National Average Enhabit % Above National Average QoPC Star Rating(1) 3.0. 3.6 20% HHCAHPS Star Rating(2) 3.7 3.9 5.4% 30-Day Hospital Readmission Rate(3) 18.2 14.5 370 bps better Standardized Protocols Motivated Clinicians Disciplined Use of Technology Superior Performance 94% of our home health agencies are 3 Stars or higher; 43% are 4 Stars or higher(1) 99% of our home health agencies are 3 Stars or higher; 83% are 4 Stars or higher(2) Percent of patients readmitted to an acute care hospital within 30 days of start of care or resumption of care 1) Quality of Patient Care (QoPC) Star Ratings as of July 2023 for dates of service (October 1, 2021 - September 30, 2022) 2) Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Ratings as of July 2023 for dates of service (January 1, 2022 - December 31, 2022) 3) Research Institute for Home Care 2022 Chartbook (data from Medicare Standard Analytics Files for CY 2021), EHAB data is as of the second quarter 2023 (All payors)

 
Enhabit Home Health & Hospice 12 Hospice Segment ($ in millions) Q2 '23 vs. '222023 2022 Net service revenue $48.5 $47.8 1.5 % Cost of services $24.1 $21.5 12.1 % Gross margin 50.3 % 55.0 % General & administrative expenses $16.1 $15.5 3.9 % Equity earnings / noncontrolling interest $— $0.1 Adjusted EBITDA $8.3 $10.7 (22.4) % % Adj. EBITDA margin 17.1 % 22.4 % Operational metrics (Actual Amounts) Total admissions 2,837 2,835 0.1 % Same-store total admissions growth (4.1) % Patient days 311,465 313,718 (0.7) % Discharged average length of stay 108 109 (0.9) % Average daily census 3,423 3,447 (0.7) % Revenue per day $156 $152 2.6 % Cost per day $77 $69 11.6 % Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 13 Hospice Segment (continued) Hospice average daily census decreased 0.7% year over year Revenue increased 1.5% over the prior year primarily due to increased Medicare reimbursement rates. • The resumption of sequestration reduced revenue approximately $0.5 million. • Revenue per day increased 2.6% year over year primarily due to increased Medicare reimbursement rates partially offset by the resumption of sequestration and patient mix. • Admissions increased 0.1% year over year. – Average daily census decreased 2.8% sequentially due to the impact of short length of stay patients. Adjusted EBITDA decreased primarily due to higher cost of services resulting from increased labor costs. • Cost per day increased 11.6% year over year primarily due to increased labor costs resulting from the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses. • Cost per day stabilized sequentially.

 
Enhabit Home Health & Hospice 14 Consolidated Adjusted EBITDA ($ in millions) Q2 2023 % of Consolidated Revenue Q2 2022 % of Consolidated Revenue Home health segment Adjusted EBITDA $42.8 $53.0 Hospice segment Adjusted EBITDA $8.3 $10.7 Home office general & administrative expenses $(27.2) (10.4) % $(23.4) (8.7) % Consolidated Adjusted EBITDA $23.9 $40.3 Home office general & administrative expenses in the above table exclude: Unusual or nonrecurring items(1) $2.6 $4.1 Stock-based compensation $2.6 $1.2 Stock-based compensation expense included in overhead allocation $0.0 $0.6 Gain on disposal or impairment of assets $(0.1) $(0.4) Home office general and administrative expenses increased as a percentage of revenue year over year primarily due to incremental costs associated with being a stand-alone company and a lower revenue base. Reconciliations to GAAP provided on pages 35 to 37 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 15 Debt & Liquidity Metrics ($ in millions) June 30, 2023 December 31, 2022 Advances under $350 million revolving credit facility, due 2027(1) $180.0 $190.0 $400 million term loan facility, due 2027(2) $377.8 $387.9 Finance lease obligations $4.0 $5.2 Total debt $561.8 $583.1 Less: Cash and cash equivalents $34.4 $22.9 Net debt $527.4 $560.2 Net debt to Adjusted EBITDA 4.75 x 3.75 x Trailing twelve-month Adjusted EBITDA $111.5 $149.3 Available liquidity(3) $90.0 $179.5 Reconciliations to GAAP provided on pages 35 to 37 (1) The Q2 2023 weighted average interest rate was 6.8% (SOFR + credit spread adjustment + 200 bps). (2) In October 2022, Enhabit entered into an interest rate swap to fix the rate on $200 million of its term loan. The swap fixes the SOFR component of the interest rate at 4.3%. (3) Cash plus the undrawn revolver balance, less letters of credit, equals $201 million as of June 30, 2023. Availability under our revolver is constrained by $111 million due to the consolidated net leverage covenant of 5.25x, resulting in net available liquidity of $90 million.

 
Enhabit Home Health & Hospice 16 Adjusted Free Cash Flow • Adjusted free cash flow decreased year over year primarily due to the reduction in Adjusted EBITDA and increase in cash interest payments. – Credit agreement entered into on June 30, 2022 in connection with separation from Encompass Health; no cash interest payments in first half of 2022 • See uses of adjusted free cash flow on slide 20. ($ in millions) $78.0 $(38.1) $10.6$(17.9) $5.4 $0.9 $38.9 Adj. Free Cash Flow YTD 2022 Adjusted EBITDA Cash Interest Payments Change in Working Capital and Other Cash Tax Payments, Net of Refunds Maintenance Capital Expenditures Adj. Free Cash Flow YTD 2023 $0 $20 $40 $60 $80 Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 17 2023 Guidance Revised as of August 9, 2023 Reconciliations to GAAP provided on pages 35 to 37 ($ in millions, except per share data) 2022 Actuals 2023 Original Guidance 2023 Revised Guidance Net service revenue $1,071.1 $1,110 to $1,140 $1,057 to $1,065 Adjusted EBITDA $149.3 $125 to $140 $100 to $107 Adjusted EPS $1.36 $0.50 to $0.89 $0.28 to $0.46

 
Enhabit Home Health & Hospice 18 Guidance Considerations • An increase of 0.7% in Medicare pricing prior to the resumption of sequestration in Q1 and Q2 • Continued shift to more non-episodic admissions • Cost per visit increase of 1% to 3% Home Health • An increase of 3.8% in Medicare pricing prior to the resumption of sequestration for Q1 through Q3 • Cost per patient day increase of 7% to 10% Hospice • Year-over-year increase in costs associated with being a stand-alone company = $9 to $10 million • Incremental expense of approximately $1 to $3 million for de novo locations • Incremental interest expense of $25 million to $27 million • Tax rate of approximately 26% • Diluted share count of approximately 50.1 million shares Consolidated

 
Enhabit Home Health & Hospice 19 Adjusted Free Cash Flow Assumptions ($ in millions) Certain cash flow items 2022 Full Year 2023 YTD 2023 Assumptions Cash interest expense $12.9 $17.9 $38 to $40 Cash income tax payments (refunds), net 11.9 (5.4) $(4) to $(5) Working capital and other 35.7 (3.9) $0 to $5 Maintenance capital expenditures 4.5 1.7 $5 to $10 Adjusted free cash flow $84.3 $38.9 $49 to $69 Reconciliations to GAAP provided on pages 35 to 37 • Cash interest payments in full year 2022 include two quarters of impact from debt incurred as part of the separation from Encompass Health. Cash interest payments in full year 2023 reflect 12 months of payments, increased interest rates, and larger SOFR spread due to increased leverage. • Cash tax payments in 2022 resulted in a prepayment of approximately $11 million as of December 31, 2022. • Use of working capital expected in back half of year due to higher accounts receivable balances and insurance payments.

 
Enhabit Home Health & Hospice 20 Uses of Adjusted Free Cash Flow ($ in millions) Growth in Core Business 2022 Full Year YTD 2023 2023 Assumptions De novos $1.2 $1.3 $2 to $4 Acquisitions(1)(2) $36.3 $2.8 TBD Debt repayments (borrowings), net(3) $(10.0) $20.0 TBD (1) On January 1, 2022, Enhabit acquired a 50% equity interest from Frontier Home Health and Hospice, LLC in a joint venture with Saint Alphonsus system which operates home health and hospice locations in Boise, Idaho. The total purchase price was $15.9 million and was funded on December 31, 2021. (2) Completed the acquisition of Specialty Home Health Care, Inc. at a purchase price of $3.1 million, with a hold back of $0.3 million expected to be released March 1, 2025. (3) Amounts in this row do not include debt incurred as part of the separation transaction from Encompass Health in 2022.

 
Enhabit Home Health & Hospice 21 Appendix

 
Enhabit Home Health & Hospice 22 Overview 103 hospice locations co-located with home health locations(1) 11 states where we are #1 or #2 in home health(2) ~69% of total Medicare home health spend occurs in states in which we operate(2) Home Health Locations Hospice Locations Home Health & Hospice State Home Health Only State (1) As of June 30, 2023 (2) Based on 2020 Home Health Medicare revenues 108 Hospice Locations(1) 255 Home Health Locations(1) We are a leading provider of home health and hospice services that strives to provide superior, cost-effective care where patients prefer it: in their homes For over 20 years, we've provided care with high-quality outcomes becoming a trusted partner of health systems, payors and other risk-bearing entities We operate nationally across 34 states with 10,000+ employees We foster an award-winning culture that is a strategic advantage in attracting and retaining talent and a main contributor to our continued success

 
Enhabit Home Health & Hospice 23 Growth Strategy Multi-faceted growth avenues with clearly defined areas of opportunity Drive organic growth at existing operations Execute on de novo strategy Evaluate strategic acquisitions Leverage care transitions expertise Expand Medicare Advantage focus Explore adjacent service offerings Currently located in states that represent ~69% of 2020 total Medicare home health spend Open 10 de novo locations per year Identify and evaluate opportunities Attractive partner due to quality of outcomes, data management capabilities, scale and market density Total Medicare beneficiaries choosing Medicare Advantage expected to continue to grow Explore adjacent verticals to further bolster our footprint in home health services

 
Enhabit Home Health & Hospice 24 Home Health Operational Metrics (net service revenue $ in millions) Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 Q1 2023 Q2 2023 Home health net service revenue $224.9 $220.2 $216.3 $215.8 $877.1 $215.8 $213.8 (Actual Amounts) Total admissions 53,309 49,399 49,739 50,048 202,495 53,943 50,975 Episodic admissions 38,971 36,106 35,487 34,572 145,136 35,032 32,628 Non-episodic admissions 14,338 13,293 14,252 15,476 57,359 18,911 18,347 Total recertifications 31,787 32,440 32,362 32,383 128,972 31,778 33,342 Episodic recertifications 25,808 25,993 25,821 25,279 102,901 23,674 23,788 Non-episodic recertifications 5,979 6,447 6,541 7,104 26,071 8,104 9,554 Total starts of care 85,096 81,839 82,101 82,431 331,467 85,721 84,317 Completed episodes 63,111 62,691 60,396 60,250 246,448 57,827 56,808 Avg. revenue per episode $3,038 $2,972 $3,009 $2,958 $2,995 $2,943 $2,913 Visits per episode 15.2 15.0 14.9 14.3 14.9 14.8 14.6 Total visits 1,228,084 1,217,447 1,175,002 1,159,420 4,779,953 1,205,700 1,205,865 Non-episodic visits 270,253 275,679 272,282 297,350 1,115,564 351,283 377,214 Cost per visit $86 $88 $92 $92 $89 $88 $91

 
Enhabit Home Health & Hospice 25 Hospice Operational Metrics (net service revenue $ in millions) Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 Q1 2023 Q2 2023 Hospice net service revenue $49.4 $47.8 $49.4 $47.4 $194.0 $49.3 $48.5 (Actual Amounts) Total admissions 3,246 2,835 2,982 2,915 11,978 3,122 2,837 Patient days 319,834 313,718 320,732 330,102 1,284,386 317,027 311,465 Discharged average length of stay 108 109 103 110 108 114 108 Average daily census 3,554 3,447 3,486 3,588 3,519 3,523 3,423 Revenue per day $154 $152 $154 $144 $151 $155 $156 Cost per day $68 $69 $71 $74 $70 $77 $77

 
Enhabit Home Health & Hospice 26 Reconciliation of Historic Segment Adjusted EBITDA of Encompass Health to Enhabit Adjusted EBITDA PLACE HOLDER – WILL NEED: • EBITDA to Net income • Adjusted EPS to reported EPS and Net income ($ in millions) Q1 2021 Q2 2021 Q3 2021 Q4 2021 FY 2021 Q1 2022 Q2 2022 FY 2022 Encompass Health Segment Adjusted EBITDA $50.8 $61.7 $46.4 $52.6 $211.5 $50.1 $43.8 $93.9 Less: Overhead allocation from Encompass Health (3.8) (4.6) (3.9) (4.4) (16.7) (3.6) (4.1) (7.7) Add: stock-based compensation included in overhead allocation 0.2 0.9 0.5 0.8 2.4 0.5 0.6 1.1 Enhabit Adjusted EBITDA $47.2 $58.0 $43.0 $49.0 $197.2 $47.0 $40.3 $87.3 Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 27 Consolidated Results – YTD 2023 ($ in millions, except per share data) Year-To-Date '23 vs. '222023 2022 Home health net service revenue $429.7 $445.1 (3.5) % Hospice net service revenue $97.7 $97.2 0.5 % Total net service revenue $527.4 $542.3 (2.7) % % of Revenue % of Revenue Cost of services 50.8 % $(268.1) 47.9 % $(260.0) 3.1 % Gross margin 49.2 % $259.3 52.1 % $282.3 (8.1) % General & administrative expenses 39.7 % $(209.4) (35.7) % $(193.7) 8.1 % Operating expenses 90.5 % $(477.5) 83.7 % $(453.7) 5.2 % Other income $(0.1) $— Equity earnings / noncontrolling interest $0.8 $1.3 Adjusted EBITDA $49.2 $87.3 (43.6) % Adjusted EBITDA margin 9.3 % 16.1 % Reported Diluted EPS $(1.44) $0.93 (254.6) % Adjusted EPS (see calculations on slides 33 and 34) $0.14 $1.02 (86.3) % General & administrative expenses in the above table exclude: Unusual or nonrecurring items that are not typical of ongoing operations(1) $4.9 $6.1 Stock-based compensation $4.1 $2.5 Gain on disposal or impairment of assets $(0.1) $(0.5) Stock-based compensation included in overhead allocation $— $1.1 Reconciliations to GAAP provided on pages 35 to 37 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 28 Home Health Segment Results – YTD 2023 ($ in millions) Year-To-Date '23 vs. '222023 2022 Net service revenue $429.7 $445.1 (3.5) % Cost of services $219.5 $216.8 1.2 % Gross margin 48.9 % 51.3 % General & administrative expenses $122.3 $116.5 5.0 % Other income $(0.1) $— Equity earnings / noncontrolling interest $0.8 $1.1 (27.3) % Adjusted EBITDA $87.2 $110.7 (21.2) % % Adj. EBITDA margin 20.3 % 24.9 % Operational metrics (Actual Amounts) Starts of care Episodic admissions 67,660 75,077 (9.9) % Non-episodic admissions 37,258 27,631 34.8 % Total admissions 104,918 102,708 2.2 % Same-store total admissions growth 0.8 % Episodic recertifications 47,462 51,801 (8.4) % Non-episodic recertifications 17,658 12,426 42.1 % Total recertifications 65,120 64,227 1.4 % Same-store total recertifications growth 0.9 % Total starts of care 170,038 166,935 1.9 % Completed episodes 114,635 125,802 (8.9) % Revenue per episode $2,928 $3,005 (2.6) % Visits per episode 14.7 15.1 (2.6) % Total visits 2,411,565 2,445,531 (1.4) % Non-episodic visits 728,497 545,932 33.4 % Cost per visit $89 $87 2.3 % Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 29 Hospice Segment Results – YTD 2023 ($ in millions) Year-To-Date '23 vs. '222023 2022 Net service revenue $97.7 $97.2 0.5 % Cost of services $48.6 $43.2 12.5 % Gross margin 50.3 % 55.6 % General & administrative expenses $32.4 $30.4 6.6 % Equity earnings / noncontrolling interest $— $0.2 Adjusted EBITDA $16.7 $23.4 (28.6) % % Adj. EBITDA margin 17.1 % 24.1 % Operational metrics (Actual Amounts) Total admissions 5,959 6,081 (2.0) % Same-store total admissions growth (6.0) % Patient days 628,492 633,552 (0.8) % Discharged average length of stay 111 109 1.8 % Average daily census 3,472 3,500 (0.8) % Revenue per day $155 $153 1.3 % Cost per day $77 $68 13.2 % Reconciliations to GAAP provided on pages 35 to 37

 
Enhabit Home Health & Hospice 30 Payor Sources As a % of Revenue Second Quarter Year To Date Fiscal Year 2022 2023 2022 2023 2022 Consolidated Medicare 78.5% 70.8% 78.8% 71.9% 78.4% Medicare Advantage 13.8% 20.3% 13.2% 19.5% 14.2% Managed Care 6.7% 7.7% 6.8% 7.5% 6.1% Medicaid 1.0% 1.2% 1.2% 1.1% 1.2% Other —% —% —% —% 0.1% Total 100.0% 100.0% 100.0% 100.0% 100.0% Home Health Medicare 74.5% 65.2% 75.0% 66.4% 73.8% Medicare Advantage 16.8% 24.9% 16.0% 24.0% 17.3% Managed Care 7.5% 8.5% 7.7% 8.2% 7.3% Medicaid 1.2% 1.4% 1.3% 1.3% 1.4% Other —% —% —% 0.1% 0.2% Total 100.0% 100.0% 100.0% 100.0% 100.0% Hospice Medicare 96.7% 95.3% 96.8% 96.0% 98.8% Managed Care 2.9% 4.1% 2.6% 4.0% 0.7% Medicaid 0.4% 0.4% 0.6% —% 0.5% Other —% 0.2% —% —% —% Total 100.0% 100.0% 100.0% 100.0% 100.0%

 
Enhabit Home Health & Hospice 31 EPS Calculation: Q2 2023 ($ in millions, except per share amounts) Adjusted EPS – Q2 2023 As Reported Impairment of Goodwill Unusual or nonrecurring items that are not typical of ongoing operations Income Tax Adjustments As Adjusted Adjusted EBITDA $23.9 $— $— $— $23.9 Impairment of goodwill (85.8) 85.8 — — — Interest expense and amortization of debt discounts & fees (10.3) — — — (10.3) Depreciation and amortization (7.7) — — — (7.7) Unusual or nonrecurring items that are not typical of ongoing operations(1) (2.6) — 2.6 — — Stock-based compensation (2.6) — — — (2.6) Gain on disposal or impairment of assets 0.1 — — — 0.1 Net loss before income taxes, including noncontrolling interests (85.0) 85.8 2.6 — 3.4 Income tax benefit (expense) 10.6 (11.1) (1.0) 0.1 (1.4) Net (loss) income attributable to Enhabit $(74.4) $74.7 $1.6 $0.1 $2.0 Diluted earnings per share $(1.49) $1.50 $0.03 $— $0.04 Diluted shares 49.8 49.8 (1) Unusual or nonrecurring items include costs associated with non-routine litigation and shareholder activism.

 
Enhabit Home Health & Hospice 32 EPS Calculation: Q2 2022 ($ in millions, except per share amounts) Adjusted EPS – Q2 2022 As Reported Unusual or nonrecurring items that are not typical of ongoing operations As Adjusted Adjusted EBITDA $40.3 $— $40.3 Depreciation and amortization (8.2) — (8.2) Unusual or nonrecurring items that are not typical of ongoing operations(1) (4.1) 4.1 — Stock-based compensation (1.2) — (1.2) Stock-based compensation included in overhead allocation (0.6) — (0.6) Gain on disposal or impairment of assets 0.4 — 0.4 Interest expense and amortization of debt discounts & fees (0.1) — (0.1) Net income before income taxes, including noncontrolling interests 26.5 4.1 30.6 Income tax expense (6.4) (1.0) (7.4) Net income attributable to Enhabit $20.1 $3.1 $23.2 Diluted earnings per share $0.41 $0.06 $0.47 Diluted shares 49.6 49.6 (1) Unusual or nonrecurring items include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 33 EPS Calculation: YTD 2023 ($ in millions, except per share amounts) Adjusted EPS – YTD 2023 As Reported Impairment of Goodwill Unusual or nonrecurring items that are not typical of ongoing operations Income Tax Adjustments As Adjusted Adjusted EBITDA $49.2 $— $— $— $49.2 Impairment of goodwill (85.8) 85.8 — — — Interest expense and amortization of debt discounts & fees (19.8) — — — (19.8) Depreciation and amortization (15.5) — — — (15.5) Unusual or nonrecurring items that are not typical of ongoing operations (4.9) — 4.9 — — Stock-based compensation (4.1) — — — (4.1) Gain on disposal or impairment of assets 0.1 — — — 0.1 Net loss before income taxes, including noncontrolling interests (80.8) 85.8 4.9 — 9.9 Income tax benefit (expense) 9.1 (11.1) (1.6) 0.5 (3.1) Net (loss) income attributable to Enhabit $(71.7) $74.7 $3.3 $0.5 $6.8 Diluted earnings per share $(1.44) $1.50 $0.07 $0.01 $0.14 Diluted shares 49.8 49.8 (1) Unusual or nonrecurring items include costs associated with shareholder activism and and non-routine litigation.

 
Enhabit Home Health & Hospice 34 EPS Calculation: FY 2022 Adjusted EPS – FY 2022 ($ in millions, except per share amounts) As Reported Unusual or nonrecurring items that are not typical of ongoing operations As Adjusted Adjusted EBITDA $87.3 $— $87.3 Depreciation and amortization (16.7) — (16.7) Unusual or nonrecurring items that are not typical of ongoing operations(1) (6.1) 6.1 — Stock-based compensation (2.5) — (2.5) Stock-based compensation included in overhead allocation (1.1) — (1.1) Gain on disposal or impairment of assets 0.5 — 0.5 Interest expense and amortization of debt discounts & fees (0.1) — (0.1) Net income before income taxes, including noncontrolling interests 61.3 6.1 67.4 Income tax expense (15.1) (1.5) (16.6) Net income attributable to Enhabit $46.2 $4.6 $50.8 Diluted earnings per share $0.93 $0.09 $1.02 Diluted shares 49.6 49.6 (1) Unusual or nonrecurring items include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 35 Reconciliation of Net (Loss) Income to Adjusted EBITDA – Consolidated ($ in millions) Second Quarter YTD 2023 2022 2023 2022 Net (loss) income $(74.1) $20.8 $(70.9) $47.5 Impairment of goodwill 85.8 — 85.8 — Income tax (benefit) expense (10.6) 6.4 (9.1) 15.1 Interest expense and amortization of debt discounts and fees 10.3 0.1 19.8 0.1 Depreciation and amortization 7.7 8.2 15.5 16.7 Unusual or nonrecurring items that are not typical of ongoing operations(1) 2.6 4.1 4.9 6.1 Stock-based compensation 2.6 1.2 4.1 2.5 Net income attributable to noncontrolling interests (0.3) (0.7) (0.8) (1.3) Gain on disposal or impairment of assets (0.1) (0.4) (0.1) (0.5) Stock-based compensation included in overhead allocation — 0.6 — 1.1 Adjusted EBITDA $23.9 $40.3 $49.2 $87.3 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 36 Reconciliation of Cash Provided by Operations to Adjusted EBITDA ($ in millions) Second Quarter YTD 2023 2022 2023 2022 Net cash provided by operating activities $9.6 $33.6 $39.2 $75.0 Interest expense, excluding amortization of debt discounts and fees 10.1 0.1 19.3 0.1 Unusual or nonrecurring items that are not typical of ongoing operations(1) 2.6 4.1 4.9 6.1 Change in assets and liabilities, excluding derivative instruments 1.2 (5.0) (15.0) (10.3) Current portion of income tax expense 0.7 7.6 1.9 16.5 Net income attributable to noncontrolling interests in continuing operations (0.3) (0.7) (0.8) (1.3) Stock-based compensation included in overhead allocation — 0.6 — 1.1 Other — — (0.3) 0.1 Adjusted EBITDA $23.9 $40.3 $49.2 $87.3 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
Enhabit Home Health & Hospice 37 Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow ($ in millions) Second Quarter YTD 2023 2022 2023 2022 Net cash provided by operating activities $9.6 $33.6 $39.2 $75.0 Cash expenditures for maintenance (1.1) (0.3) (1.7) (2.6) Other working capital adjustments (0.5) (0.4) (1.0) (0.9) Distributions paid to noncontrolling interests of consolidated affiliates — (0.2) (2.5) (0.7) Items non-indicative of ongoing operating performance: Unusual or nonrecurring items that are not typical of ongoing operations(1) 2.6 4.1 4.9 6.1 Stock-based compensation included in overhead allocation — 0.6 — 1.1 Adjusted free cash flow $10.6 $37.4 $38.9 $78.0 (1) Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism; in 2022, they include costs associated with the strategic alternatives review.

 
v3.23.2
Cover
Aug. 09, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 09, 2023
Entity Registrant Name Enhabit, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41406
Entity Tax Identification Number 47-2409192
Entity Address, Address Line One 6688 N. Central Expressway
Entity Address, Address Line Two Suite 1300
Entity Address, City or Town Dallas
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75206
City Area Code 214
Local Phone Number 239-6500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol EHAB
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001803737
Enhabit (NYSE:EHAB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Enhabit.
Enhabit (NYSE:EHAB)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Enhabit.